When was Karuna Therapeutics founded?

Karuna Therapeutics was founded in 2009.

Where is Karuna Therapeutics located?

Karuna Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts.

Who is the current CEO of Karuna Therapeutics?

Steven M Paul of Karuna Therapeutics. They have also founded 1 company.

How many employees does Karuna Therapeutics have?

As of Nov 19, 2025, the latest employee count at Karuna Therapeutics is 53.

Is Karuna Therapeutics a funded company?

Karuna Therapeutics is a funded company, having raised a total of $136M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of Karuna Therapeutics?

Karuna Therapeutics' latest funding was a $***** Series B round on Apr 01, 2019, with participation from 10 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.41B in funding in 2026 to date.

What is the annual revenue of Karuna Therapeutics?

Annual revenue of Karuna Therapeutics is less than $1M as on Dec 31, 2023

Where does Karuna Therapeutics rank among its competitors?

Karuna Therapeutics ranks 602nd amongst 2861 active competitors, of which 973 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Karuna Therapeutics?

Karuna Therapeutics' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Immuneel secured the most recent funding round in June, 2026.

Karuna Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapies for the treatment of psychosis and cognitive impairment. The company's product line include KarXT, is an oral M1 and M4-preferring muscarinic agonist for the treatment of schizophrenia and psychosis in Alzheimer's disease.

Website: karunatx.com
Email ID: *****@karunatx.com
Part Of
Registered Address: Boston, Massachusetts

Key Metrics

Founded Year

2009

Location

Boston, United States

Stage

Acquired

Total Funding

$136M in 7 rounds

Latest Funding Round

Series B, Apr 01, 2019, $*****

Investors

Sofinnova Investments & 12 more

Ranked

602^nd among 2861 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2023

Employee Count

53 as on Nov 19, 2025

Similar Companies

Jazz Pharmaceuticals & 577 more

Exit Details

Acquired by Bristol-Myers Squibb (Dec 22, 2023)

View Karuna Therapeutics' full profile

Karuna Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
KARUNA THERAPEUTICS, INC. CIN: 270605902 , United States, Active	Dec 31, 1999	$0 - $1M (As on Dec 31, 2023)	317 (As on Dec 31, 2023)	-

Karuna Therapeutics got acquired by Bristol-Myers Squibb on Dec 22, 2023.

Click here to take a look at Karuna Therapeutics's acquisition in detail

Karuna Therapeutics has raised a total funding of $136M over 7 rounds. Its latest funding round was a Series B round on Apr 01, 2019 for $*****. 10 investors participated in its latest round. Karuna Therapeutics has 13 institutional investors.

Here is the list of recent funding rounds of Karuna Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 01, 2019	1807881	Series B	9441566	6572456	9009435	5903411
Mar 18, 2019	5944481	Series B	9913727	5604319	6687977	Fidelity Investments & 7 more
Aug 02, 2018	5808167	Series A	5633959	6424244	9111850	Arch Venture Partners & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Karuna Therapeutics's funding rounds and investors

The founders of Karuna Therapeutics is Andrew Miller. Steven M Paul is the CEO of Karuna Therapeutics.

Here are the details of Karuna Therapeutics' key team members:

Andrew Miller: Founder of Karuna Therapeutics. They serve on the board of 1 company.
Steven M Paul: Co-Founder of Karuna Therapeutics.

View details of Karuna Therapeutics's Founder profiles and Board Members

Karuna Therapeutics' employee count trend

Karuna Therapeutics has 53 employees as of Nov 25. Here is Karuna Therapeutics's employee count trend over the years:

Employee count trend for Karuna Therapeutics

Uncover Karuna Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Karuna Therapeutics include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Karuna Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
602nd	Karuna Therapeutics 2009, Boston (United States), Acquired	Developer of therapies for the treatment of psychosis and cognitive impairment	$136M	Fidelity Investments, Nan Fung Life Sciences ... & 11 others	47/100